Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
Combo of T-cell therapy, newly FDA-approved drug and another immunotherapeutic agent kept cancer at bay for three out of four patients with metastatic Merkel cell carcinoma. The findings will be presented June 5 at the annual meeting of the American Society of Clinical Oncology.